Friday, 20 Apr 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
16 Apr 2018 Slide of the day 23 FDA Approved Biologics for Use in Rheumatology
11 Apr 2018 Social Shingrix captured 90% of shingles vaccine market, w/ greater efficacy & CDC endorsement, plus is NOT a live vaccine & could be used with biologics. While cost is the same, it has more nuisance side effect & no studies/data in RA, CTD. https://t.co/lycVu8JrQq
09 Apr 2018 Social 2015 US Pharma donated $116 million to Pt advocacy groups. For example Patients for Biologics Safety & Access (who opposes biosimilar substitution and includes Crohn’s & Colitis, Arthritis & Lupus Foundations) accepted $9.1 million from drug companies https://t.co/i3WDjNHu6f
05 Apr 2018 News IL-6 Inhibition Most Effective in Polycyclic Systemic JIA
05 Apr 2018 News Rituximab May Halt ILD in Antisynthetase Syndrome Myositis
29 Mar 2018 Social Large BSRBR study of Serious infections w/ biologics shows SI=5.51 per 100PY for all; tocilizumab was higher vs ETN (HR 1.22; 1.02 to 1.47) & certolizumab lower or equal to ETN. 30-day mortality following SI was 10.4% (95% CI 9.2% to 11.6%). https://t.co/h5BieShHpH
27 Mar 2018 News Anakinra May Attenuate Stroke Outcomes
09 Mar 2018 News FDA Panel Votes to Favor High Dose Xeljanz in Ulcerative Colitis
06 Mar 2018 News Abatacept Efficacy in JIA
22 Feb 2018 Social https://t.co/ru9Ej9aMDu of Derm mtg in San Diego has several new biologic therapies of Atopic Dermatitis, including baricitinib, upadacitinib, ASN002 (JAK/SYK inhibitor) and anti IL-33 (ANB020). https://t.co/cOm6jcPRCq
22 Feb 2018 Social FDA grants "breakthrough" status to Pfizers Xeljanz (tofacitinib) for phase III trials in atopic dermatitis https://t.co/hzdMTjxmg1
19 Feb 2018 Social Correction: 2018 AAD presentations on upadacitinib (Abbvies JAK1 inhibitor) in moderate to severe atopic dermatitis shows improvements in pruritus at week 1 and improvement in the extent and severity of skin lesions at week 2. https://t.co/PWjHqpgtWg
14 Feb 2018 News Abatacept Improves GvHD Outcomes
12 Feb 2018 Social RT @uptoTate: Switching to biosimilars are non inferior in IBD. Dr. U. Mahadevan #RWCS @RheumNow https://t.co/kxbZXNZETe
11 Feb 2018 ACR Video Dr. George Martin: New Molecular Therapies in Metastatic Melanoma
10 Feb 2018 Social RT @uptoTate: “Roughly 50% of our patients will stay on biologics therapy after 5 years.” Dr. M. Genovese #RWCS @RheumNow https://t.co/Z6dG…
06 Feb 2018 News Biosimilar Reports - February 2018
02 Feb 2018 Social Canadian retrospective cohort review shows that biologic patients treated with denosumab do not have higher rates of serious or opportunistic infections (compared to biologic alone) https://t.co/G5N9DfvYFZ
29 Jan 2018 News Less Cardiovascular Risk with Abatacept in Rheumatoid Arthritis
29 Jan 2018 Social Mavilimumab (anti-GMCSF MAb) effective in 442 RA pts with slow onset of effect in 1st 6 mos. 65% achieved LDAS and 41% DAS–CRP <2.6 remission by wk 122. But modest efficacy, no better than golimumab and concern about Pulm toxicty has halted development https://t.co/GcOhgouYWx